716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy

Abstract

MIBC has few adjuvant treatment (tx) options. ctDNA analysis is a promising approach for selecting pts potentially suitable for checkpoint inhibitors. In IMvigor010, ctDNA positivity identified pts with high-risk muscle-invasive urothelial cancer who may derive disease-free and overall survival (DFS/OS) benefit from adjuvant atezo. ctDNA– pts had a low relapse risk without improved outcomes with atezo vs observation, suggesting they may be spared adjuvant tx (Powles ESMO IO 2020). Following on these data, IMvigor011 is studying adjuvant atezo vs pbo in pts with high-risk MIBC who are ctDNA+ post cystectomy.